How Bristol-Myers Squibb Can Transform Oncology Research and Drug Development with Agentic AI

Agentic AI in oncology research is quickly moving from an interesting concept to a practical way to reduce cycle time, improve decision quality, and connect teams across discovery, translational science, clinical development, safety, and real-world evidence. For Bristol Myers Squibb (BMS), the opportunity is not “more AI experiments.” It’s building repeatable, governed agentic workflows that make high-stakes oncology work measurably faster and more reliable, without creating compliance or operational risk.

Over the last few years, many life sciences organizations proved that language models can summarize papers, draft emails, and answer questions. But that’s not where the real value is. In 2026, the edge comes from agentic AI in oncology research: systems that can plan work, use tools, retrieve the right evidence, run structured steps, and deliver outputs that humans can trust and approve. Done well, this is how teams move beyond pilots and turn AI into durable operational capability.

This guide breaks down what agentic AI in oncology research actually is, where it fits across the oncology pipeline, how to implement it in a GxP-aligned way, and which KPIs matter so results don’t get trapped in “pilot purgatory.”

What “Agentic AI” Means in Pharma (and What It’s Not)

Definition: Agentic AI vs. GenAI Chatbots

Agentic AI in oncology research refers to AI systems designed to achieve a goal through multi-step execution. Instead of responding once to a prompt, an agent can plan, take actions, validate results, and iterate, while staying within human-defined guardrails.

A useful way to think about it: a chatbot answers questions. An agent finishes tasks.

In practice, agentic AI in oncology research typically includes these capabilities:

1. Goal-directed planning: breaks a complex objective into steps

2. Tool use: queries databases, searches internal knowledge, calls analytics code, drafts documents, triggers workflows

3. Memory and context: retains project-specific constraints and prior decisions (with permissioning)

4. Iteration and self-checking: compares outputs to requirements and reruns steps when needed

5. Human-in-the-loop controls: routes sensitive decisions for approval

6. Evaluation and logging: produces traces that can be reviewed, tested, and audited

This differs from adjacent categories that many teams already use:

• Traditional ML: predicts outcomes or flags patterns, but rarely orchestrates multi-step work

• LLM copilots: draft or summarize content, but don’t reliably execute end-to-end workflows

• Rule-based automation: deterministic and brittle, struggles when inputs vary or context changes

Agentic AI in oncology research matters because oncology R&D doesn’t fail due to lack of intelligence. It fails due to friction: scattered evidence, inconsistent processes, slow handoffs, and work that’s repeated across teams in slightly different formats. Agents reduce that friction when they’re built as structured workflows with clear inputs and outputs.

Why Oncology Is the Best Testbed for Agentic AI

Oncology is uniquely suited to agentic AI in oncology research for three reasons.

• First, the data is multimodal and high-dimensional. Meaningful oncology decisions combine genomics, transcriptomics, pathology images, radiology, clinical endpoints, safety data, and increasingly real-world evidence.

• Second, the knowledge landscape changes daily. New targets, combinations, resistance mechanisms, and trial results constantly reshape what “good” looks like.

• Third, failure is expensive. Late-stage trial failure, avoidable protocol amendments, or slow enrollment aren’t just operational issues; they reshape portfolio economics. Agentic AI in oncology research is valuable precisely because it can shorten learn cycles and improve trial design decisions earlier.

Why This Matters for Bristol Myers Squibb (BMS) Specifically

Oncology R&D Challenges Where Agents Can Move the Needle

BMS operates at a scale where small percentage improvements compound. The biggest opportunities for agentic AI in oncology research tend to sit in the gaps between teams and systems, where work becomes manual, slow, or inconsistently executed.

Common friction points include:

• Target selection uncertainty and translational gaps between preclinical signals and clinical response

• Biomarker complexity, assay feasibility, and patient stratification that changes as data accumulates

• Recruitment friction due to narrow eligibility criteria, site burden, and inconsistent prescreening workflows

• Protocol amendments driven by feasibility issues discovered too late

• Safety signal triage volume and reporting timelines that strain pharmacovigilance operations

• Data silos across research, clinical operations, safety, and medical affairs that slow evidence assembly

Agentic AI in oncology research is well suited to these challenges because they are not single-model problems. They’re orchestration problems that require retrieval, tool use, structured reasoning, and standardized outputs.

Outcomes That Would Be “Material” for BMS

In a large oncology portfolio, “material” outcomes look like measurable shifts in time, probability, and cost.

Agentic AI in oncology research can support outcomes such as:

• Reduced time-to-candidate and time-to-IND by compressing literature-to-hypothesis-to-experiment cycles

• Improved probability of technical and regulatory success by strengthening evidence packages and consistency checks

• Faster study startup and enrollment through better protocol feasibility and site selection

• Lower cost per insight by reducing repetitive analysis and rework

• Fewer protocol amendments by catching operational risks earlier

• Stronger real-world evidence narratives for payers and HTA bodies by making RWE analysis more reproducible and better documented

The key is to connect each agentic workflow to one or two KPIs that leadership already cares about. Without that, agentic AI in oncology research risks becoming another set of impressive demos.

High-Impact Agentic AI Use Cases Across the Oncology Pipeline

Before diving deep, here are seven high-value use cases that often deliver quick wins while building foundations for broader scale:

1. Literature and competitive intelligence agent

2. Target and biomarker hypothesis agent

3. IND evidence compilation agent

4. Protocol optimization and amendment-prevention agent

5. Site feasibility and startup agent

6. Pharmacovigilance triage and narrative drafting agent

7. RWE cohort building and sensitivity analysis agent

What makes these ideal entry points for agentic AI in oncology research is that they have clear inputs, repeatable outputs, and natural human approval checkpoints.

Discovery and Target Identification Agents

Inputs for discovery-focused agentic AI in oncology research often include:

• Internal omics datasets and preclinical reports

• CRISPR screens and pathway databases

• External literature and patents

• Prior program postmortems and decision memos

Agent actions:

• Retrieve and synthesize evidence by target, pathway, tumor type, and mechanism

• Score hypotheses using a transparent rubric (novelty, tractability, competitive crowding, safety risk)

• Identify contradictory findings and request clarification or additional data

• Propose next-best experiments, including controls and decision criteria

Outputs:

• Ranked target shortlists with mechanistic rationale

• Evidence maps showing supporting and opposing data

• Risk flags: potential toxicity signals, target expression concerns, novelty limitations, competitive overlap

• “What would change my mind” experiment plans

KPIs:

• Cycle time to produce a target shortlist

• Reproducibility of the shortlist across teams

• Hit rate of prioritized targets advancing to validation milestones

• Reduction in time spent on manual literature synthesis

A practical design principle: successful teams avoid monolithic “do everything” agents. They break risk into smaller, targeted use cases and validate them sequentially. That pattern is especially relevant for agentic AI in oncology research, where errors can propagate into expensive decisions.

Biomarker and Patient Stratification Agents

Biomarker work sits at the intersection of science, assay reality, clinical feasibility, and regulatory expectations. That’s exactly where agentic AI in oncology research can provide leverage.

Inputs:

• Transcriptomics, ctDNA, IHC results, proteomics

• Imaging features and pathology interpretations

• EHR phenotype definitions and real-world endpoints

• Assay performance constraints and lab SOPs

Agent actions:

• Propose multimodal feature combinations tied to mechanistic hypotheses

• Suggest cohort definitions and run sensitivity checks (where possible via approved analytics tools)

• Draft biomarker validation plans aligned to the study stage

• Perform feasibility checks: assay availability, turnaround time, sample requirements, site capabilities

Outputs:

• Biomarker hypotheses with traceable rationale

• Patient stratification rules with explainability notes

• Assay feasibility summaries and risk registers

• Draft documentation to support internal review

KPIs:

• Biomarker-positive response enrichment over time

• Reduced number of failed biomarkers due to feasibility issues

• Faster biomarker documentation cycles

• Fewer late-stage changes to stratification logic

Preclinical and Translational Experiment Orchestration

Many organizations think of agentic AI in oncology research as primarily “reading and writing.” In reality, the most durable value often comes from orchestration: ensuring experiments are logged consistently, anomalies are surfaced early, and learn cycles tighten.

Agent actions:

• Monitor experiment metadata and detect missing fields or inconsistent parameters

• Identify outlier results and recommend replication or root-cause checks

• Generate structured weekly summaries for cross-functional teams

• Prompt for protocol adherence checkpoints and deviation capture

Outputs:

• Experiment logbook summaries

• Deviation reports and anomaly triage queues

• Team-ready updates that reduce meeting overhead

KPIs:

• Fewer protocol deviations

• Faster time from experiment completion to actionable readout

• Improved traceability of decisions back to source data

IND-Enabling Documentation and Evidence Assembly

IND preparation is where friction, inconsistency, and version sprawl show up brutally. Agentic AI in oncology research can help by making evidence assembly more structured and less dependent on heroics.

Agent actions:

• Pull relevant evidence from approved internal repositories and prior submissions

• Draft structured summaries with traceability back to sources

• Cross-check consistency across modules (terminology, dosing rationale, nonclinical claims)

• Produce gap lists that route to owners early

Outputs:

• First-pass drafts for review

• Traceable evidence packets

• Consistency check reports and gap trackers

KPIs:

• Reduced time to produce initial drafts

• Fewer review cycles caused by missing evidence or inconsistent claims

• Improved audit readiness through better lineage and documentation consistency

Agentic AI in Clinical Development: Trial Design, Startup, and Execution

Clinical development is where agentic AI in oncology research can deliver measurable operational outcomes quickly, especially when focused on decision support rather than autonomous action.

Protocol Design and Amendment-Prevention Agents

Protocol amendments are costly, slow enrollment, and add burden to sites. A protocol-focused agent can act as a structured reviewer that uses historical patterns and feasibility simulations.

Agent actions:

• Compare draft protocols to historical protocols and known deviation drivers

• Analyze eligibility criteria complexity and predict enrollment impact

• Suggest endpoint and visit schedule adjustments to reduce site burden

• Generate a protocol risk register with mitigation options

Outputs:

• Optimized protocol drafts for review

• Enrollment forecasts under different criteria scenarios

• Amendment risk assessment and mitigation plan

KPIs:

• Fewer amendments per study

• Faster internal approval cycles due to clearer risk documentation

• Improved enrollment velocity and reduced screen failure rate

Site Feasibility, Startup, and Monitoring Agents

Site selection and startup often suffer from inconsistent feasibility assessments and scattered performance data. Agentic AI in oncology research can standardize feasibility packages and highlight operational risks earlier.

Agent actions:

• Rank sites based on prior performance in similar indications and operational metrics

• Draft feasibility questionnaires tailored to protocol specifics

• Summarize feasibility responses and flag high-risk constraints

• Prioritize monitoring based on early risk signals (data latency, query load, deviation patterns)

Outputs:

• Ranked site lists with rationale

• Feasibility summaries and risk flags

• Monitoring priority queues for teams

KPIs:

• Reduced time from site outreach to activation

• Faster query resolution times

• Fewer late data issues that trigger downstream delays

Patient Identification and Recruitment Agents (Ethical and Compliant)

Patient identification is a powerful use case, but it must be designed with privacy, fairness, and governance from day one. The most practical pattern is decision support: the agent suggests candidates or cohorts from de-identified data, and coordinators make final determinations.

Agent actions:

• Map eligibility criteria to de-identified EHR patterns

• Generate explainable “why eligible” rationales

• Track recruitment funnel metrics and diversity progress signals

Outputs:

• Candidate pools and prescreening lists

• Coordinator-friendly eligibility rationales

• Recruitment dashboards that highlight bottlenecks

KPIs:

• Faster enrollment

• Lower screen fail rate

• Improved ability to monitor diversity goals and recruitment equity

Medical Writing and CSR Assembly Agents

Medical writing is a natural fit for agentic AI in oncology research when the agent is grounded in approved datasets and writing standards, and when QC is integrated as an explicit step.

Agent actions:

• Draft narrative sections tied to approved analysis outputs

• Run consistency checks across endpoints, populations, and terminology

• Generate QC checklists and flag mismatches

Outputs:

• Draft CSR sections for medical writer review

• Consistency reports to accelerate QC

KPIs:

• Reduced cycle time from database lock to draft completion

• Fewer QC findings and fewer rework loops

Post-Market and Medical Affairs: Safety, RWE, and Scientific Engagement

Agentic AI in oncology research does not stop at approval. In many organizations, the post-market environment is where volume spikes and evidence generation becomes continuous.

Pharmacovigilance Triage and Case Processing Agents

Pharmacovigilance is a high-volume workflow that benefits from structured drafting, prioritization, and de-duplication, while keeping humans in control of final reporting decisions.

Agent actions:

• Intake and de-duplication support

• Coding suggestions and narrative drafting aligned to internal standards

• Prioritization of serious and unexpected signals for expert review

• Assemble audit trails of what data was used and what decisions were made

Outputs:

• Case drafts and narratives for review

• Signal dashboards and prioritization queues

• Trace logs for auditability

KPIs:

• PV case processing time

• On-time reporting performance

• Quality metrics from QC review

RWE and HEOR Agents for Evidence Generation

RWE work is often slowed by repeated cohort building, inconsistent sensitivity analyses, and heavy documentation burden. Agentic AI in oncology research can help standardize the workflow and make outputs more reproducible.

Agent actions:

• Draft cohort definitions and analysis plans

• Execute sensitivity analysis workflows via approved analytics tooling

• Document methodology clearly for internal review and external scrutiny

• Generate payer-appropriate evidence summaries that remain grounded in the underlying analysis

Outputs:

• Study specifications and analysis drafts

• Reproducible analysis artifacts and documentation

• Summary decks for internal stakeholders

KPIs:

• Time-to-analysis and time-to-insight

• Reproducibility and transparency scores in internal review

• Reduced rework due to missing documentation

Field Medical and Publication Intelligence Agents

Medical affairs teams need timely, accurate, indication-specific updates. Agentic AI in oncology research can reduce the noise by curating and structuring updates by tumor type, mechanism, and audience.

Agent actions:

• Monitor publications and congress updates (from approved sources)

• Create structured digests by topic and relevance

• Draft briefing documents and internal FAQs for review

Outputs:

• Curated evidence digests

• Briefing documents and evidence maps

KPIs:

• Time saved in literature monitoring

• Reduced duplicative effort across teams

• Faster alignment on scientific narratives

Architecture Blueprint: What BMS Needs to Make Agentic AI Real

Successful agentic AI in oncology research is less about a single model choice and more about a reliable “agent stack” that can be governed, tested, and observed.

The Agent Stack (Core Components)

A practical stack for agentic AI in oncology research typically includes:

1. Orchestrator: planning and execution engine that manages steps and branching logic

2. Tool layer: connectors to search, internal knowledge, LIMS, CTMS, EDC, safety systems, analytics environments

3. Memory: project context and prior decisions, governed by role-based access

4. Evaluation layer: tests and guardrails that measure factuality, completeness, and traceability

5. Observability: logs, traces, cost controls, performance monitoring, and error reporting

The advantage of this approach is that it supports multiple workflows without rebuilding from scratch each time. It also makes it easier to standardize controls across teams.

Data Foundations: Multimodal and Governed Access

Oncology data is complex, and agentic AI in oncology research will only be as good as its access patterns and governance.

Key requirements include:

• Least-privilege access to internal systems and datasets

• Strong data lineage: who accessed what, when, for what purpose

• Metadata consistency to support traceability and audit readiness

• Clear separation between regulated and non-regulated contexts

Many enterprises also benefit from an entity layer that standardizes core objects such as targets, biomarkers, trials, tumor types, endpoints, adverse events, and therapies. Whether that takes the form of a knowledge graph or well-designed metadata services, the goal is the same: make retrieval and reasoning consistent.

Human-in-the-Loop Design

In regulated contexts, agentic AI in oncology research should be designed around explicit approval checkpoints.

Common patterns include:

• Approval gates for any GxP-critical output

• Two-person review rules for high-impact deliverables

• Escalation paths when the agent detects uncertainty, conflicting sources, or missing data

• Confidence and provenance indicators that encourage appropriate skepticism

This helps prevent automation bias, where people trust outputs more than they should simply because they’re well written.

Governance, Risk, and Compliance (GxP-Ready Agentic AI)

The number one barrier to scaling agentic AI in oncology research is not model performance. It’s governance. When controls are not built up front, shadow usage spreads, trust collapses, and security or legal teams respond with blanket restrictions that slow everything down.

Key Risks to Address Up Front

A realistic risk register for agentic AI in oncology research includes:

• Unsupported claims and hallucinations that appear confident

• Data leakage involving PHI, IP, or partner data

• Model drift that changes outputs over time and breaks reproducibility

• Automation bias and over-reliance in decision-making workflows

• Lack of audit trails and inability to explain who did what, when, and why

These risks are manageable, but only if agentic workflows are treated as production systems, not experiments.

Controls That Make Agentic AI Deployable in Pharma

Teams that scale agentic AI in oncology research successfully tend to standardize a set of controls:

• Risk-based validation strategy: define intended use, risk level, and required evidence of performance

• Prompt and tool governance: versioning, approvals, change control, and rollback procedures

• Grounding to approved sources: constrain retrieval and require provenance for critical claims

• Red-teaming: test for privacy leakage, security vulnerabilities, bias, and failure modes

• Logging and monitoring: capture runs, inputs, tools invoked, outputs, approvals, and exceptions

A key mindset shift: if an agent is producing outputs that affect regulated work, it should be evaluated like any other critical system component. The evaluation harness is not optional; it is the mechanism that makes scaling safe.

Regulatory and Standards Touchpoints (Non-Legal Guidance)

Rather than claiming a tool is automatically compliant, the practical approach is to design agentic AI in oncology research to align with well-understood expectations:

• Traceability and documentation discipline consistent with GxP principles

• Privacy-by-design controls appropriate for patient data handling

• Standard operating procedures for use, review, and change control

• Fit-for-purpose testing aligned to the workflow’s impact

This keeps the conversation grounded in operational reality: can the organization reproduce outputs, explain decisions, and demonstrate control?

Implementation Roadmap for BMS (From Pilot to Platform)

Agentic AI in oncology research scales when teams build iteratively: start small, prove value, lock down governance, then expand across functions.

Phase 1 (0–90 Days): Pick 1–2 High-ROI, Low-Risk Workflows

The goal in the first 90 days is to deliver measurable outcomes without needing deep system integration.

Good starting points:

• Literature and patent intelligence agent for a specific tumor area

• Protocol optimization agent that produces decision support outputs for review

• PV intake triage support agent focused on drafting and prioritization

What to do in this phase:

• Define one owner and one cross-functional reviewer group

• Establish baseline metrics before the agent is introduced

• Specify inputs and outputs in writing, including required review steps

• Create a “golden set” of example cases to evaluate quality and consistency

Phase 2 (3–6 Months): Integrate with Systems and Build an Evaluation Harness

This phase is where many teams either level up or stall. The difference is whether evaluation and governance mature alongside integration.

Focus areas:

• Integrate with the systems that matter: CTMS, LIMS, EDC, document repositories, safety systems, analytics tools

• Implement role-based access control aligned to real job functions

• Build automated tests: factuality checks, completeness checks, traceability checks, formatting requirements

• Add observability: logs, run histories, exception handling, and cost monitoring

The outcome should be repeatability: the same workflow produces reliably similar results under controlled conditions, with deviations explainable.

Phase 3 (6–12 Months): Scale Across Indications and Functions

Once the platform patterns are proven, scaling becomes a matter of templating and governance.

What scaling can look like:

• Template agents per tumor area with shared tools and consistent evaluation

• Shared “R&D agent platform” that supports discovery, clinical ops, safety, and medical affairs

• A formal operating model: Center of Excellence, workflow owners, and review boards

This is where agentic AI in oncology research becomes an organizational capability rather than a team-level experiment.

Phase 4 (12+ Months): Closed-Loop Optimization

The long-term value comes from closed-loop systems that learn from outcomes.

Examples:

• Agents that propose protocol changes and quantify uncertainty based on enrollment results

• PV agents that continuously improve prioritization based on QC feedback

• RWE agents that refine cohort definitions based on sensitivity findings and stakeholder review

Closed-loop does not mean fully autonomous. It means the system improves systematically, with human oversight and measured performance.

Measuring ROI: KPIs That Matter in Oncology R&D

Agentic AI in oncology research should be judged by operational and scientific outcomes, not by novelty.

Discovery and Translational KPIs

• Cycle time to hypothesis shortlist

• Time from hypothesis to experiment plan approval

• Experiment iteration speed and “learn cycle” duration

• Robustness indicators: replication rate, consistency across datasets

Clinical Operations KPIs

• Site activation and startup time

• Enrollment velocity and screen failure rate

• Amendment frequency and leading drivers

• Data query rates and query resolution time

Safety and RWE KPIs

• PV case processing cycle time

• On-time reporting rates and QC findings

• RWE time-to-analysis and reproducibility in internal review

• Signal detection lead time where applicable

Enterprise KPIs

• Time saved per function (validated with sampling, not guesswork)

• Adoption metrics by role and workflow

• Risk reduction indicators: fewer QC findings, improved audit outcomes, fewer uncontrolled tools

A useful rule: for every agentic AI in oncology research workflow, pick one outcome KPI and one risk KPI. Teams need both to scale responsibly.

What Most Competitors Miss (and How to Do Better)

Many articles talk about “AI in pharma” in abstract terms. BMS-level execution demands specificity.

The most common gaps:

• Vague descriptions of AI rather than mapping agent actions to real tools and checkpoints

• No evaluation methodology, which makes scaling unsafe and trust fragile

• Weak governance design, especially around versioning and approvals

• No clear boundaries for where agents should not operate autonomously

• Underuse of multimodal oncology data, where much of the value lives

Agentic AI in oncology research becomes compelling when it’s designed as a governed system: clear ownership, structured workflows, measurable KPIs, and audit-ready traces.

Conclusion: A Practical Path for BMS to Lead with Agentic AI

BMS doesn’t need more disconnected AI pilots. It needs a repeatable way to deploy agentic AI in oncology research across the pipeline, with governance that scales as complexity grows.

The practical path is straightforward:

• Start with measurable workflows where agents reduce cycle time and rework

• Build the agent stack and evaluation harness early, not after success

• Embed human approvals and traceability for regulated or high-impact outputs

• Scale by templating: reuse tools, controls, and evaluation patterns across teams

• Optimize continuously using real-world performance metrics, not assumptions

To see what this looks like in practice, book a StackAI demo: https://www.stack-ai.com/demo